Systematic Review of Crizanlizumab: A New Parenteral Option to Reduce Vaso‐occlusive Pain Crises in Patients with Sickle Cell Disease

Han, Jin; Saraf, Santosh L.

doi:10.1002/phar.2409

Cited by 25 publications

(28 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…34,35 A post hoc subgroup analysis and a retrospective trial (SUCCESSOR trial) assessed the efficacy of crizanlizumab, using both the data set from the same original SUSTAIN trial and data corroborating the activity of high-dose crizanlizumab at preventing VOEs. [35][36][37] These findings led to the US Food and Drug Administration (FDA) approval of crizanlizumab for the prevention of VOEs in patients with SCD of all genotypes who are >16 years of age. 31 In the subgroup analysis, patients who received only high-dose crizanlizumab had a lower annual crisis rate than those who received crizanlizumab with concomitant hydroxyurea (difference from placebo: −50.0% vs −32.1%).…”

Section: Sustain Trialmentioning

confidence: 99%

P-Selectin Blockade in the Treatment of Painful Vaso-Occlusive Crises in Sickle Cell Disease: A Spotlight on Crizanlizumab

Karki¹,

Kutlar²

2021

JPR

View full text Add to dashboard Cite

Microvascular vaso-occlusion driven pain crisis is the hallmark of sickle cell disease with profound morbidity and increased mortality. Selectins, most notably P-selectins have an integral role in this phenomenon. P-selection was first identified in 1989. In 2019, after 3 decades of basic, translational, and clinical work with this pathway, the US Food and Drug Administration approved a P-selectin antibody, crizanlizumab to reduce frequency of pain crisis in patients more than 16 years with sickle cell disease. We review the fundamentals of P-selectin pathobiology, P-selectin blocking agents, clinical data with the use of crizanlizumab and prospects of this novel class of drugs in the context of other treatments for painful vaso-occlusive episodes.

show abstract

Section: Sustain Trialmentioning

confidence: 99%

P-Selectin Blockade in the Treatment of Painful Vaso-Occlusive Crises in Sickle Cell Disease: A Spotlight on Crizanlizumab

Karki¹,

Kutlar²

2021

JPR

View full text Add to dashboard Cite

show abstract

“…15 Because crizanlizumab affects the recruitment of leukocytes, it is unknown if this affects infection risk. 20…”

Section: Dosing Administration and Safetymentioning

confidence: 99%

“…Crizanlizumab offers an alternative for patients who do not tolerate or fail hydroxyurea. 20 As the SUSTAIN trial included both patients receiving hydroxyurea and those who were not, crizanlizumab may be safely administered as monotherapy or in combination. 14 Crizanlizumab can be used regardless of SCD subtype, as all groups demonstrated benefit from crizanlizumab.…”

Section: Relevance To Patient Care and Clinical Practices And Medication Costmentioning

confidence: 99%

Crizanlizumab for the Prevention of Vaso-Occlusive Pain Crises in Sickle Cell Disease

Stevens

Hix

Gildon

2021

Journal of Pharmacy Technology

View full text Add to dashboard Cite

Objective: To review the efficacy and safety of crizanlizumab (Adakveo) in the prevention of vaso-occlusive pain crises in sickle cell disease. Data Sources: An English-language literature search of PubMed, MEDLINE, and Ovid (1946 to January 2021) was completed using the terms crizanlizumab, SEG101, SelG1, and sickle cell disease. Manufacturer prescribing information, article bibliographies, and data from clinicaltrials.gov were incorporated in the reviewed data. Study Selection/Data Extraction: All studies registered on clinicaltrials.gov were incorporated in the reviewed data. Data Synthesis: Crizanlizumab is the first monoclonal antibody approved for sickle cell disease to reduce the frequency of vaso-occlusive crises. One phase 2 clinical trial and a post hoc analysis of the trial have been published. Relevance to Patient Care and Clinical Practice: Crizanlizumab is a monthly intravenous infusion approved by the Food and Drug Administration for patients with sickle cell disease 16 years of age and older to reduce the frequency of vaso-occlusive crises. Conclusion: Crizanlizumab appears to be an efficacious therapy for patients with sickle cell disease to reduce the frequency of vaso-occlusive crises. Concerns include drug cost and administration. Long-term benefits and risks have not been determined.

show abstract

“…P-selectin, an adhesion molecule expressed on activated vascular endothelial cells and platelets, facilitates cell-to-cell and cell-to-endothelium interactions that are involved in the pathogenesis of VOC in SCD. 33 The SUSTAIN trial, a multicenter randomized double blind study, showed that crizanlizumab decreased the incidence of VOC by 45% in patients with or without HU. Crizanlizumab also prolonged the median time to the first and second VOC.…”

Section: Approved Pharmacological Drugs For Scd In Current Clinical Pmentioning

confidence: 99%

“… 34 There are several ongoing clinical trials that are trying to explore crizanlizumab’s safety and efficacy in pediatric patients with SCD. 33 …”

Section: Approved Pharmacological Drugs For Scd In Current Clinical Pmentioning

confidence: 99%

Challenges in the Management of Sickle Cell Disease During SARS-CoV-2 Pandemic

Alsayegh

Mousa

2020

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

The management of sickle cell disease (SCD) and its complications in the COVID-19 era is very challenging. The recurrent sickling process in SCD causes tissue hypoxemia and micro-infarcts, resulting in end organ damage. Since the outbreak of SARS-CoV-2 pandemic, little data has been published about SCD concerning clinical presentation with COVID-19 and management. Hydroxyurea has been the cornerstone of management in children and adults with SCD, with evidence of its effect on controlling end organ damage. There are several anti-sickling drugs that have been approved recently that might have an additive value toward the management of SCD and its complications. The role of simple and exchange transfusions is well established and should always be considered in the management of various complications. The value of convalescent plasma has been demonstrated in small case series, but large randomized controlled studies are still awaited. Immunomodulatory agents may play a role in reducing the damaging effects of cytokines storm that contributes to the morbidity and mortality in advanced cases. Prophylactic anticoagulation should be considered in every management protocol because SCD and COVID-19 are thrombogenic conditions. Management proposals of different presentations of patients with SCD and COVID-19 are outlined.

show abstract

Systematic Review of Crizanlizumab: A New Parenteral Option to Reduce Vaso‐occlusive Pain Crises in Patients with Sickle Cell Disease

Cited by 25 publications

References 38 publications

P-Selectin Blockade in the Treatment of Painful Vaso-Occlusive Crises in Sickle Cell Disease: A Spotlight on Crizanlizumab

P-Selectin Blockade in the Treatment of Painful Vaso-Occlusive Crises in Sickle Cell Disease: A Spotlight on Crizanlizumab

Crizanlizumab for the Prevention of Vaso-Occlusive Pain Crises in Sickle Cell Disease

Challenges in the Management of Sickle Cell Disease During SARS-CoV-2 Pandemic

Contact Info

Product

Resources

About